Clinical trial
Fulvestrant in Treating Patients With Advanced Prostate Cancer
NCT00244998 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00244998 |
|---|---|
| Title | Fulvestrant in Treating Patients With Advanced Prostate Cancer |
| Official title | Phase II Study of Fulvestrant (Faslodex®) in Androgen Independent Prostate Cancer |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | fulvestrant |
| Enrollment | 20 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Jun 1, 2012 |
| First posted | Oct 27, 2005 |
| Last update posted | Mar 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: